Search By Condition or Specialty.

Full Name	Amondys 45™ (casimersen)
Drug	Amondys 45
Manufacturer	Sarepta Therapeutics, Inc.
Route of Administration	Intravenous
Site of Care	Home or Healthcare Facility
Approved Indication	Treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 45 skipping
Disease	Duchenne Muscular Dystrophy (DMD)
Therapeutic Area	Neurology
Enrollment Form Link	Enrollment Form
Phone Number	800-356-5034
Fax Number	877-339-4602
Product Website	amondys45.com
Patient Resources	Alex Rezcalla Foundation, Jett Foundation, Muscular Dystrophy Association, and Parent Project Muscular Dystrophy

Full Name	deflazacort
Drug	deflazacort
Manufacturer	Upsher-Smith (tablets) and Cranbury (oral suspension)
Route of Administration	Oral
Site of Care	Home
Approved Indication	Treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older
Disease	Duchenne Muscular Dystrophy (DMD)
Therapeutic Area	Neurology
Enrollment Form Link	Tablets Enrollment Form Oral suspension Enrollment Form
Phone Number	800-605-1524
Fax Number	877-765-6254
Patient Resources	Alex Rezcalla Foundation, Jett Foundation, Muscular Dystrophy Association, and Parent Project Muscular Dystrophy

Full Name	Elevidys™ (delandistrogene moxeparvovec-rokl)
Drug	Elevidys
Manufacturer	Sarepta Therapeutics, Inc.
Route of Administration	Intravenous
Site of Care	Healthcare Facility
Approved Indication	Treatment of Duchenne muscular dystrophy (DMD) in individuals at least 4 years of age: For patients who are ambulatory and have a confirmed mutation in the DMD gene For patients who are non-ambulatory and have a confirmed mutation in the DMD gene
Disease	Duchenne muscular dystrophy (DMD)
Therapeutic Area	Neurology; Genetics; Cell & Gene Therapy
Enrollment Form Link	Enrollment Form
Phone Number	800-870-8931
Fax Number	877-694-2546
Product Website	elevidyshcp.com
Patient Resources	Alex Rezcalla Foundation, Jett Foundation, Muscular Dystrophy Association, and Parent Project Muscular Dystrophy

Full Name	Emflaza® (deflazacort)
Drug	Emflaza
Manufacturer	PTC Therapeutics, Inc.
Route of Administration	Oral
Site of Care	Home or Healthcare Facility
Approved Indication	Treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older
Disease	Duchenne Muscular Dystrophy (DMD)
Therapeutic Area	Neurology, Genetics
Enrollment Form Link	Enrollment Form
Phone Number	800-605-1524
Fax Number	877-765-6254
Product Website	hcp.emflaza.com
Patient Resources	Alex Rezcalla Foundation, Jett Foundation, Muscular Dystrophy Association, and Parent Project Muscular Dystrophy

Full Name	Exondys 51® (eteplirsen)
Drug	Exondys 51
Manufacturer	Sarepta Therapeutics, Inc.
Route of Administration	Intravenous
Site of Care	Home or Healthcare Facility
Approved Indication	The treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping
Disease	Duchenne Muscular Dystrophy (DMD)
Therapeutic Area	Neurology
Enrollment Form Link	Enrollment Form
Phone Number	800-356-5034
Fax Number	877-339-4602
Product Website	exondys51.com
Patient Resources	Alex Rezcalla Foundation, Jett Foundation, Muscular Dystrophy Association, and Parent Project Muscular Dystrophy

Full Name	JAYTHARI (deflazacort)
Drug	deflazacort
Manufacturer	Zydus Lifesciences Limited
Route of Administration	Oral
Site of Care	Home
Approved Indication	The treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age and older
Disease	Duchenne Muscular Dystrophy (DMD)
Therapeutic Area	Neurology; Genetics
Enrollment Form Link	Enrollment Form
Phone Number	(847) 393-4099
Fax Number	(877) 860-1978
Patient Resources	Alex Rezcalla Foundation, Jett Foundation, Muscular Dystrophy Association, and Parent Project Muscular Dystrophy

Full Name	Viltepso® (viltolarsen)
Drug	Viltepso
Manufacturer	NS Pharma
Route of Administration	Intravenous
Site of Care	Home or Healthcare Facility
Approved Indication	The treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping
Disease	Duchenne Muscular Dystrophy (DMD)
Therapeutic Area	Neurology
Enrollment Form Link	Viltepso Enrollment Form
Phone Number	800-759-0445
Fax Number	877-286-3620
Product Website	viltepso.com
Patient Resources	Alex Rezcalla Foundation, Jett Foundation, Muscular Dystrophy Association, and Parent Project Muscular Dystrophy

Full Name	Vyondys 53® (golodirsen)
Drug	Vyondys 53
Manufacturer	Sarepta Therapeutics, Inc.
Route of Administration	Intravenous
Site of Care	Home or Healthcare Facility
Approved Indication	The treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping
Disease	Duchenne Muscular Dystrophy (DMD)
Therapeutic Area	Neurology
Enrollment Form Link	Vyondys 53 Enrollment Form
Phone Number	800-356-5034
Fax Number	877-339-4602
Product Website	vyondys53.com
Patient Resources	Alex Rezcalla Foundation, Jett Foundation, Muscular Dystrophy Association, and Parent Project Muscular Dystrophy